TY - JOUR
T1 - Deoxysphingolipid precursors indicate abnormal sphingolipid metabolism in individuals with primary and secondary disturbances of serine availability
AU - Ferreira, C. R.
AU - Goorden, S. M. I.
AU - Soldatos, A.
AU - Byers, H. M.
AU - Ghauharali-van der Vlugt, J. M. M.
AU - Beers-Stet, F. S.
AU - Groden, C.
AU - van Karnebeek, C. D.
AU - Gahl, W. A.
AU - Vaz, F. M.
AU - Jiang, X.
AU - Vernon, H. J.
PY - 2018
Y1 - 2018
N2 - Patients with primary serine biosynthetic defects manifest with intellectual disability, microcephaly, ichthyosis, seizures and peripheral neuropathy. The underlying pathogenesis of peripheral neuropathy in these patients has not been elucidated, but could be related to a decrease in the availability of certain classical sphingolipids, or to an increase in atypical sphingolipids. Here, we show that patients with primary serine deficiency have a statistically significant elevation in specific atypical sphingolipids, namely deoxydihydroceramides of 18–22 carbons in acyl length. We also show that patients with aberrant plasma serine and alanine levels secondary to mitochondrial disorders also display peripheral neuropathy along with similar elevations of atypical sphingolipids. We hypothesize that the etiology of peripheral neuropathy in patients with primary mitochondrial disorders is related to this elevation of deoxysphingolipids, in turn caused by increased availability of alanine and decreased availability of serine. These findings could have important therapeutic implications for the management of these patients.
AB - Patients with primary serine biosynthetic defects manifest with intellectual disability, microcephaly, ichthyosis, seizures and peripheral neuropathy. The underlying pathogenesis of peripheral neuropathy in these patients has not been elucidated, but could be related to a decrease in the availability of certain classical sphingolipids, or to an increase in atypical sphingolipids. Here, we show that patients with primary serine deficiency have a statistically significant elevation in specific atypical sphingolipids, namely deoxydihydroceramides of 18–22 carbons in acyl length. We also show that patients with aberrant plasma serine and alanine levels secondary to mitochondrial disorders also display peripheral neuropathy along with similar elevations of atypical sphingolipids. We hypothesize that the etiology of peripheral neuropathy in patients with primary mitochondrial disorders is related to this elevation of deoxysphingolipids, in turn caused by increased availability of alanine and decreased availability of serine. These findings could have important therapeutic implications for the management of these patients.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85047211279&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29789193
U2 - https://doi.org/10.1016/j.ymgme.2018.05.001
DO - https://doi.org/10.1016/j.ymgme.2018.05.001
M3 - Article
C2 - 29789193
SN - 1096-7192
VL - 124
SP - 204
EP - 209
JO - Molecular Genetics and Metabolism
JF - Molecular Genetics and Metabolism
IS - 3
ER -